Search Results - "Moti, N"

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial by Wohl, David A, Yazdanpanah, Yazdan, Baumgarten, Axel, Clarke, Amanda, Thompson, Melanie A, Brinson, Cynthia, Hagins, Debbie, Ramgopal, Moti N, Antinori, Andrea, Wei, Xuelian, Acosta, Rima, Collins, Sean E, Brainard, Diana, Martin, Hal

“…Bictegravir co-formulated with emtricitabine and tenofovir alafenamide as a fixed-dose combination is recommended for treatment of HIV-1-infection and might be…”
Get full text

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study by Hagins, Debbie, Kumar, Princy, Saag, Michael, Wurapa, Anson K., Brar, Indira, Berger, Daniel, Osiyemi, Olayemi, Hileman, Corrilynn O., Ramgopal, Moti N., McDonald, Cheryl, Blair, Christiana, Andreatta, Kristen, Collins, Sean E., Brainard, Diana M., Martin, Hal

“…With the highest rates of HIV/AIDS in the United States, Black Americans are still underrepresented in HIV medical research. BRAAVE (NCT03631732) is a…”
Get full text

Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial by Ogbuagu, Onyema, Molina, Jean-Michel, Chetchotisakd, Ploenchan, Ramgopal, Moti N, Sanchez, William, Brunetta, Jason, Castelli, Francesco, Crofoot, Gordon E, Hung, Chien-Ching, Ronot-Bregigeon, Sylvie, Margot, Nicolas A, Wang, Hui, Dvory-Sobol, Hadas, Rhee, Martin S, Segal-Maurer, Sorana

“…Abstract Background Lenacapavir is a long-acting human immunodeficiency virus type 1 (HIV-1) capsid inhibitor for treatment of HIV-1 infection. We evaluated…”
Get full text

HIV rebound in HIV controllers is associated with a specific fecal microbiome profile by Cai, Yanhui, Podlaha, Ondrej, Deeks, Steven G., Brinson, Cynthia, Ramgopal, Moti N., DeJesus, Edwin, Mills, Anthony, Shalit, Peter, Abdel‐Mohsen, Mohamed, Zhang, Liao, Vries, Christiaan R., Vendrame, Elena, SenGupta, Devi, Wallin, Jeffrey J.

“…HIV infection is associated with gut dysbiosis, and microbiome variability may affect HIV control when antiretroviral therapy (ART) is stopped. The TLR7…”
Get full text

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial by Ramgopal, Moti N, Castagna, Antonella, Cazanave, Charles, Diaz-Brito, Vicens, Dretler, Robin, Oka, Shinichi, Osiyemi, Olayemi, Walmsley, Sharon, Sims, James, Di Perri, Giovanni, Sutton, Kenneth, Sutherland-Phillips, Denise, Berni, Alessandro, Latham, Christine L, Zhang, Feifan, D'Amico, Ronald, Pascual Bernáldez, Miguel, Van Solingen-Ristea, Rodica, Van Eygen, Veerle, Patel, Parul, Chounta, Vasiliki, Spreen, William R, Garges, Harmony P, Smith, Kimberly, van Wyk, Jean

“…Cabotegravir plus rilpivirine is the only approved complete long-acting regimen for the maintenance of HIV-1 virological suppression dosed every 2 months. The…”
Get full text

A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod by Riddler, Sharon A., Benson, Constance A., Brinson, Cynthia, Deeks, Steven G., DeJesus, Edwin, Mills, Anthony, Para, Michael F., Ramgopal, Moti N., Cai, Yanhui, Zheng, Yanan, Zhang, Liao, Jiang, Wendy, Liu, Xiaopeng, Verrill, Donovan, Lim, Daina, de Vries, Christiaan R., Wallin, Jeffrey J., Vendrame, Elena, SenGupta, Devi

“…Introduction Vesatolimod is a Toll-like receptor-7 (TLR7) agonist in clinical development as part of a combination regimen for human immunodeficiency virus…”
Get full text

Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study by Akil, Bisher, Blick, Gary, Hagins, Debbie P, Ramgopal, Moti N, Richmond, Gary J, Samuel, Rafik M, Givens, Naomi, Vavro, Cindy, Song, Ivy H, Wynne, Brian, Ait-Khaled, Mounir

“…The Phase III VIKING-3 study demonstrated that dolutegravir (DTG) 50 mg twice daily was efficacious in antiretroviral therapy (ART)-experienced subjects…”
Get more information

Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin by Moti, N, Malcolm, T, Hamoudi, R, Mian, S, Garland, G, Hook, C E, Burke, G A A, Wasik, M A, Merkel, O, Kenner, L, Laurenti, E, Dick, J E, Turner, S D

“…Cancer stem cells or tumour-propagating cells (TPCs) have been identified for a number of cancers, but data pertaining to their existence in lymphoma so far…”
Get full text

Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial by Mills, Anthony M, Rizzardini, Giuliano, Ramgopal, Moti N, Osiyemi, Olayemi O, Bogner, Johannes R, Hagins, Debbie P, Paredes, Roger, Reynes, Jacques, Rockstroh, Jürgen K, Carr, Andrew, Su, Feng-Hsiu, Klopfer, Stephanie O, Eves, Karen, Plank, Rebeca M, Correll, Todd, Fox, Michelle C

“…Doravirine and islatravir is an investigational, once-daily regimen with high antiviral potency, favourable safety and tolerability, and a low propensity for…”
Get full text

Origin of the dengue virus outbreak in Martin County, Florida, USA 2013 by Teets, Frank D., Ramgopal, Moti N., Sweeney, Kristen D., Graham, Amanda S., Michael, Scott F., Isern, Sharon

“…After a 75-year absence from Florida, substantial local transmission of dengue virus (DENV) occurred in Key West, Monroe County, Florida in 2009 and continued…”
Get full text

392 Isolation and characterisation of lymphoma stem cells by Moti, N, Turner, S.D

Get full text

Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial by Ogbuagu, Onyema, Molina, Jean-Michel, Chetchotisakd, Ploenchan, Ramgopal, Moti N, Sanchez, William, Brunetta, Jason, Castelli, Francesco, Crofoot, Gordon E, Hung, Chien-Ching, Ronot-Bregigeon, Sylvie, Margot, Nicolas A, Wang, Hui, Dvory-Sobol, Hadas, Rhee, Martin S, Segal-Maurer, Sorana

“…Lenacapavir is a long-acting HIV-1 capsid inhibitor for treatment of HIV-1 infection. We evaluated the efficacy and safety of lenacapavir in combination with…”
Get full text

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial by Squires, Kathleen, Cahn, Pedro, Lombaard, Johan, DeJesus, Edwin, Lai, Ming-Tain, Rodgers, Anthony, Kumar, Sushma, Sklar, Peter, Nguyen, Bach-Yen, Hanna, George J, Hwang, Carey, Martins, Marcelo, Bloch, Mark Theo, Baker, David Alfred, Roth, Norman, Moore, Richard James, McMahon, James, Rieger, Armin, Zoufaly, Alexander, Zangerle, Robert, Smaill, Fiona, Rachlis, Anita, Perez, Carlos, Campos Barker, Maria Isabel E., Wolff Reyes, Marcelo, Laursen, Alex Lund, Molina, Jean-Michel, Yazdanpanah, Yazdan, Cotte, Laurent, Raffi, Francois, Morlat, Philippe, Girard, Pierre-Marie, Katlama, Christine, Rockstroh, Juergen K., Arasteh, Keikawus, Stoehr, Albrecht, Stellbrink, Hans-Juergen, Stoll, Matthias, Schuermann, Dirk, Faetkenheuer, Gerd, Bogner, Johannes, Gori, Andrea, Coltan, Gabriel, Constandis, Felicia, Erscoiu, Simona Manuela, Pokrovsky, Vadim Valentinovich, Shuldyakov, Andrey Anatolyevich, Ryamova, Elena Pavlovna, Kulagin, Valeriy Viktorovich, Tsybakova, Olga Aleksandrovna, Orlova-Morozova, Elena, Shimonova, Tatyana Evgenyevna, Kozyrev, Oleg Anatolyevich, Orrell, Catherine, Lombaard, Johannes Jurgens, Botes, Margaretha Elizabeth, Portilla, Joaquin, Gatell, Josep Maria, Perez, Maria Jesus, Arribas, Jose Ramon, Negredo, Eugenia, Podzamczer, Daniel, Troya, Jesus, De los Santos, Ignacio, Berenguer, Juan, Williams, Ian G., Johnson, Margaret A., Schembri, Gabriel, Gompels, Mark, Fox, Julie Meriel, Taylor, Steven John, Kegg, Stephen, Hagins, Debbie P., Osiyemi, Olayemi O., Prelutsky, David James, Ramgopal, Moti N., Dretler, Robin, DeJesus, Edwin, Sloan, Louis, Lewis, Stanley T., Clay, Patrick G., Bellos, Nicholaos C., Montero, Jose, Creticos, Catherine, Shamblaw, David, Valdes, Martin, Felizarta, Franco Antonio, Slim, Jihad, Lalezari, Jacob Paul, Ruane, Peter Jerome, Cade, Jerry L., Campo, Rafael E., Blick, Gary, Mayer, Cynthia, Daar, Eric, Kumar, Princy N., Swindells, Susan, Castro, Jose Guillermo, Santiago, Lizette, Santana-Bagur, Jorge L.

“…Doravirine is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with a pharmacokinetic profile supporting once-daily dosing, and potent in-vitro…”
Get full text

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial by Squires, Kathleen, Cahn, Pedro, Lombaard, Johan, DeJesus, Edwin, Lai, Ming-Tain, Rodgers, Anthony, Lupinacci, Lisa, Kumar, Sushma, Hwang, Carey, Martin, Elizabeth Anne, Osiyemi, Olayemi O., Prelutsky, David James, Scarsella, Anthony John, Dretler, Robin, DeJesus, Edwin, Sims, James, Clay, Patrick G., Bellos, Nicholaos C., Creticos, Catherine, Shamblaw, David, Mogyoros, Miguel, Terrelonge, Antonio E., Valdes, Martin, Tashima, Karen T., Robbins, William J., Felizarta, Franco Antonio, Elion, Richard A., Slim, Jihad, Lalla-Reddy, Sujata N., Mills, Anthony, Dietz, Craig A., Rubin, David Scott, Rondon, Juan Carlos, Cook, Paul P., Daar, Eric, Kumar, Princy N., Swindells, Susan, Castro, Jose Guillermo, Santiago, Lizette, Martins, Marcelo, Cahn, Pedro Enrique, Lopardo, Gustavo D., Porteiro, Norma, Baker, David Alfred, Roth, Norman, Finlayson, Robert James, McMahon, James, Rieger, Armin, Zangerle, Robert, Smaill, Fiona, Walmsley, Sharon L., Conway, Brian, Rachlis, Anita, Smith, Graham H.R., Afani, Alejandro, Chahin, Carolina Eugenia, Gerstoft, Jan, Weis, Nina, Laursen, Alex Lund, Molina, Jean-Michel, Cotte, Laurent, Raffi, Francois, Girard, Pierre-Marie, Katlama, Christine, Esser, Stefan, Stoll, Matthias, Schuermann, Dirk, Faetkenheuer, Gerd, Bogner, Johannes, Lutz, Thomas, Jaeger, Hans, Gori, Andrea, Coltan, Gabriel, Constandis, Felicia, Erscoiu, Simona Manuela, Prisacariu, Liviu-Jany, Rugina, Sorin, Pokrovsky, Vadim Valentinovich, Ryamova, Elena Pavlovna, Kulagin, Valeriy Viktorovich, Tsybakova, Olga Aleksandrovna, Voronin, Evgeniy, Shimonova, Tatyana Evgenyevna, Orrell, Catherine, de Jager, Marleen, Mallolas, Josep, Perez Elias, Maria Jesus, Gatell, Josep M., Arribas Lopez, Jose Ramon, Podzamczer Palter, Daniel, Pulido Ortega, Federico, Troya Garcia, Jesus, De los Santos Gil, Ignacio, Berenguer Berenguer, Juan, Johnson, Margaret A., Schembri, Gabriel, Clarke, Amanda, Gompels, Mark, Fox, Julie Meriel, Dockrell, David Harold

“…Doravirine is a novel, non-nucleoside reverse transcriptase inhibitor that has shown non-inferior efficacy to ritonavir-boosted darunavir, with a superior…”
Get full text

1596. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results by Ogbuagu, Onyema, DeJesus, Edwin, Berhe, Mezgebe, Richmond, Gary J, Ruane, Peter J, Sinclair, Gary I, Ramgopal, Moti N, Sanchez, William, Crofoot, Gordon E, Margot, Nicolas A, Wang, Hui, Dvory-Sobol, Hadas, Rhee, Martin, Baeten, Jared, Segal-Maurer, Sorana

“…Abstract Background Lenacapavir (LEN) is a highly potent, long-acting, first-in-class inhibitor of HIV-1 capsid protein for the treatment of HIV-1 infection in…”
Get full text

Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial by Ogbuagu, Onyema, Segal-Maurer, Sorana, Ratanasuwan, Winai, Avihingsanon, Anchalee, Brinson, Cynthia, Workowski, Kimberly, Antinori, Andrea, Yazdanpanah, Yazdan, Trottier, Benoit, Wang, Hui, Margot, Nicolas, Dvory-Sobol, Hadas, Rhee, Martin S, Baeten, Jared M, Molina, Jean-Michel

“…Lenacapavir, a first-in-class HIV-1 capsid inhibitor, is in development as a long-acting agent for treating and preventing HIV-1. We aimed to evaluate the…”
Get full text

1155Origin of the dengue virus outbreak in Martin County, Florida, USA 2013 by Ramgopal, Moti N., Dahya, Vishal, Robinson, Marjorie, Isern, Sharon, Teets, Frank, Michael, Scott

Get full text

The performance validation of disturbance observer based on comparison between motion control frequency and current control frequency by Ohkubo, H., Shimono, T., Moti, N.

“…Recently, a lot of robots and industrial machines with disturbance observer (DOB) have been put to practical use all over the world. By using DOB, acceleration…”
Get full text